331 related articles for article (PubMed ID: 17726343)
1. Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.
Barone FC; Barton ME; White RF; Legos JJ; Kikkawa H; Shimamura M; Kuratani K; Kinoshita M
Pharmacology; 2008; 81(1):11-7. PubMed ID: 17726343
[TBL] [Abstract][Full Text] [Related]
2. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
4. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
[TBL] [Abstract][Full Text] [Related]
5. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
[TBL] [Abstract][Full Text] [Related]
6. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
Funatsu T; Takeuchi A; Hirata T; Keto Y; Akuzawa S; Sasamata M
Eur J Pharmacol; 2007 Nov; 573(1-3):190-5. PubMed ID: 17658508
[TBL] [Abstract][Full Text] [Related]
7. Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.
Harada D; Ikeda Y; Nosaka Y; Kobayashi K; Manabe H
J Dermatol Sci; 2008 Sep; 51(3):215-9. PubMed ID: 18539440
[No Abstract] [Full Text] [Related]
8. Action of a Novel PDE4 inhibitor ZL-n-91 on lipopolysaccharide-induced acute lung injury.
Tang HF; Lu JJ; Tang JF; Zheng X; Liang YQ; Wang XF; Wang YJ; Mao LG; Chen JQ
Int Immunopharmacol; 2010 Apr; 10(4):406-11. PubMed ID: 20074667
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
[TBL] [Abstract][Full Text] [Related]
11. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
Harada D; Tsukumo Y; Takashima Y; Manabe H
Eur J Pharmacol; 2006 Feb; 532(1-2):128-37. PubMed ID: 16442096
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of a novel, orally active PDE4 inhibitor.
Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
[TBL] [Abstract][Full Text] [Related]
13. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke.
Martorana PA; Beume R; Lucattelli M; Wollin L; Lungarella G
Am J Respir Crit Care Med; 2005 Oct; 172(7):848-53. PubMed ID: 15961691
[TBL] [Abstract][Full Text] [Related]
14. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
Makhay MM; Houslay MD; O'Donnell JM
Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
[TBL] [Abstract][Full Text] [Related]
15. Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats.
Sakura M; Masuda H; Matsuoka Y; Yokoyama M; Kawakami S; Kihara K
BJU Int; 2009 Jan; 103(2):264-9. PubMed ID: 18710439
[TBL] [Abstract][Full Text] [Related]
16. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis.
Videla S; Vilaseca J; Medina C; Mourelle M; Guarner F; Salas A; Malagelada JR
J Pharmacol Exp Ther; 2006 Feb; 316(2):940-5. PubMed ID: 16254133
[TBL] [Abstract][Full Text] [Related]
18. Effect of change in an inhibitory neurotransmitter of the myenteric plexus on the pathogenetic mechanism of irritable bowel syndrome subgroups in rat models.
Xu JR; Luo JY; Shang L; Kong WM
Chin J Dig Dis; 2006; 7(2):89-96. PubMed ID: 16643336
[TBL] [Abstract][Full Text] [Related]
19. Cold-restraint stress increases rat fecal pellet output and colonic transit.
Barone FC; Deegan JF; Price WJ; Fowler PJ; Fondacaro JD; Ormsbee HS
Am J Physiol; 1990 Mar; 258(3 Pt 1):G329-37. PubMed ID: 2316647
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase type 4 inhibitor prevents acute lung injury induced by cardiopulmonary bypass in a rat model.
Hamamoto M; Suga M; Nakatani T; Takahashi Y; Sato Y; Inamori S; Yagihara T; Kitamura S
Eur J Cardiothorac Surg; 2004 May; 25(5):833-8. PubMed ID: 15082290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
